Last reviewed 2026-04-22 · How we verify

Course A1 + Vin

Course A1 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents in Course A1 to disrupt microtubule formation and induce apoptosis in cancer cells.

Course A1 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents in Course A1 to disrupt microtubule formation and induce apoptosis in cancer cells. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric acute myeloid leukemia (AML).

At a glance

Mechanism of action

This is a multi-agent chemotherapy combination used in pediatric cancer treatment. Vincristine is a vinca alkaloid that binds to tubulin and prevents microtubule assembly, leading to cell cycle arrest and death. Course A1 typically refers to a standardized induction chemotherapy protocol that may include additional agents such as daunorubicin, cytarabine, and L-asparaginase, which work through complementary mechanisms including DNA intercalation and protein synthesis inhibition.

Approved indications

• Pediatric acute lymphoblastic leukemia (ALL)
• Pediatric acute myeloid leukemia (AML)

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Peripheral neuropathy
• Nausea and vomiting
• Mucositis
• Infection

Key clinical trials

• CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Course A1 + Vin CI brief — competitive landscape report
• Course A1 + Vin updates RSS · CI watch RSS
• Children's Cancer Group, China portfolio CI